| A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug–drug … X Li, S Frechen, D Moj, T Lehr, M Taubert, C Hsin, G Mikus, PJ Neuvonen, ... Clinical Pharmacokinetics 59, 781-808, 2020 | 50 | 2020 |
| Assessment of pharmacokinetic drug–drug interactions in humans: in vivo probe substrates for drug metabolism and drug transport revisited U Fuhr, C Hsin, X Li, W Jabrane, F Sörgel Annual review of pharmacology and toxicology 59, 507-536, 2019 | 38 | 2019 |
| Reactive electrophilic oxylipins trigger a heat stress-like response through HSFA1 transcription factors M Muench, CH Hsin, E Ferber, S Berger, MJ Mueller Journal of experimental botany 67 (21), 6139-6148, 2016 | 27 | 2016 |
| A clinical drug‐drug interaction study assessing a novel drug transporter phenotyping cocktail with adefovir, sitagliptin, metformin, pitavastatin, and digoxin C Trueck, C Hsin, O Scherf‐Clavel, E Schaeffeler, R Lenssen, M Gazzaz, ... Clinical pharmacology & therapeutics 106 (6), 1398-1407, 2019 | 26 | 2019 |
| Drinking ethanol has few acute effects on CYP2C9, CYP2C19, NAT2, and P‐glycoprotein activities but somewhat inhibits CYP1A2, CYP2D6, and intestinal CYP3A: so what? M Gazzaz, M Kinzig, E Schaeffeler, M Jübner, C Hsin, X Li, M Taubert, ... Clinical Pharmacology & Therapeutics 104 (6), 1249-1259, 2018 | 17 | 2018 |
| Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin C Hsin, MS Stoffel, M Gazzaz, E Schaeffeler, M Schwab, U Fuhr, ... Scientific Reports 10 (1), 12457, 2020 | 14 | 2020 |
| First‐in‐human study with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients M Anliker‐Ort, J Dingemanse, C Hsin, M Richard, E Huehn, G Sabattini, ... Basic & Clinical Pharmacology & Toxicology 131 (2), 114-128, 2022 | 4 | 2022 |
| Response to "Impact of Acute Alcohol Exposure on P-Glycoprotein Function at the Blood-Brain Barrier Assessed Using 11 C-Metoclopramide PET Imaging". C Hsin, U Fuhr, C Trueck Clinical Pharmacology and Therapeutics 105 (4), 814-814, 2018 | 3 | 2018 |
| Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel U Schilling, CH Hsin, S Delahaye, A Krause, H Wuelfrath, A Halabi, ... Clinical and Translational Science 15 (8), 1906-1915, 2022 | 2 | 2022 |
| Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy … I Zenklusen, CH Hsin, U Schilling, M Kankam, A Krause, M Ufer, ... Clinical Pharmacokinetics, 1-9, 2022 | 2 | 2022 |
| Pharmacokinetics, pharmacodynamics and safety of the novel C‐X‐C chemokine receptor 3 antagonist ACT‐777991: Results from the first‐in‐human study in healthy adults ML Boof, M Géhin, C Voors‐Pette, CH Hsin, V Sippel, DS Strasser, ... British Journal of Clinical Pharmacology 90 (2), 588-599, 2024 | 1 | 2024 |
| Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists C Hsin, J Dingemanse, A Henrich, C Bernaud, M Gehin, A Krause Biomolecules 13 (9), 1365, 2023 | 1 | 2023 |
| In vitro validation of an in vivo phenotyping drug cocktail for major drug transporters in humans C Hsin, A Kuehne, Y Gu, G Jedlitschky, Y Hagos, D Gründemann, U Fuhr European Journal of Pharmaceutical Sciences 186, 106459, 2023 | 1 | 2023 |
| Pharmacokinetics, pharmacodynamics, and safety of the novel CXCR3 antagonist ACT-777991: Results from the first-in-human study in healthy adults. ML Boof, M Géhin, C Voors-Pette, CH Hsin, V Sippel, DS Strasser, ... British Journal of Clinical Pharmacology, 2023 | | 2023 |
| Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist M Anliker‐Ort, C Hsin, A Krause, M Pfister, J van den Anker, ... Pharmacology Research & Perspectives 11 (4), e01112, 2023 | | 2023 |
| Methods to quantify activities of clinically relevant membrane transporters in vitro and in vivo C Hsin Universität zu Köln, 2021 | | 2021 |
| Haplotypes of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin CH Hsin, M Stoffel, M Gazzaz, E Schaeffeler, M Schwab, X Li, U Fuhr, ... Naunyn-Schmiedebergs Arch. Pharmacol. 393 (SUPPL 1), 78-79, 2020 | | 2020 |
| A cocktail study to assess pharmacokinetic interactions of acute ethanol intake C Trueck, M Gazzaz, M Kinzig, E Schaeffeler, M Juebner, CH Hsin, X Li, ... Naunyn-Schmiedebergs Arch. Pharmacol. 391, S24-1, 2018 | | 2018 |
| Lack of mutual pharmacokinetics DDIS for a novel transporter phenotyping cocktail CH Hsin, M Kinzig, E Schaeffeler, R Lenssen, M Taubert, C Trueck, ... Naunyn-Schmiedebergs Arch. Pharmacol. 391, S44-1, 2018 | | 2018 |
